CY2391B1 - Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin. - Google Patents

Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin.

Info

Publication number: CY2391B1
Authority: CY; Cyprus
Prior art keywords: rapamycin; cyclosporin; treatment; pharmaceutical compositions; transplant rejection
Prior art date: 1996-07-30

Application number

CY0300086A

Other languages

English (en)

Inventor

Gerhard Zenke

Hendrik J Schuurman

Barbara Haeberlin

Armin Meinzer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-30

Filing date

2003-11-28

Publication date

2004-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2391(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-30 Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en

1997-03-18 Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en

2003-11-28 Application filed by Novartis Ag filed Critical Novartis Ag

2004-09-10 Publication of CY2391B1 publication Critical patent/CY2391B1/xx

Links

229930105110 Cyclosporin A Natural products 0.000 title abstract 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 2
108010036949 Cyclosporine Proteins 0.000 title abstract 2
206010052779 Transplant rejections Diseases 0.000 title abstract 2
230000001363 autoimmune Effects 0.000 title abstract 2
229960001265 ciclosporin Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
230000004968 inflammatory condition Effects 0.000 title 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 2
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000035897 transcription Effects 0.000 abstract 2
238000013518 transcription Methods 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
-1 e.g. Chemical compound 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Graft Or Block Polymers (AREA)
Medicinal Preparation (AREA)

CY0300086A 1996-07-30 2003-11-28 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin. CY2391B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9615942.1A GB9615942D0 (en)	1996-07-30	1996-07-30	Organic compounds
GBGB9705684.0A GB9705684D0 (en)	1997-03-18	1997-03-18	Organic compounds

Publications (1)

Publication Number	Publication Date
CY2391B1 true CY2391B1 (en)	2004-09-10

Family

ID=26309775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY0300086A CY2391B1 (en)	1996-07-30	2003-11-28	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin.

Country Status (14)

Country	Link
US (2)	US6239124B1 (fr)
EP (2)	EP0956034B1 (fr)
JP (2)	JP3942641B2 (fr)
AT (2)	ATE222502T1 (fr)
AU (1)	AU730781B2 (fr)
CA (1)	CA2261666C (fr)
CY (1)	CY2391B1 (fr)
DE (2)	DE69714861T2 (fr)
DK (2)	DK0956034T3 (fr)
ES (2)	ES2270948T3 (fr)
NZ (1)	NZ333657A (fr)
PT (2)	PT1208847E (fr)
SI (1)	SI1208847T1 (fr)
WO (1)	WO1998004279A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1033128B2 (fr) *	1993-09-28	2011-11-23	R.P. Scherer GmbH	Procédé de production de capsules en gélatine molle
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
DK0956034T3 (da) *	1996-07-30	2002-12-16	Novartis Ag	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
GB9825632D0 (en) *	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
GB9826882D0 (en)	1998-12-07	1999-01-27	Novartis Ag	Organic compounds
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
EP1181034B1 (fr) *	1999-05-10	2010-07-21	Paolo Brenner	Combinaisons d'agents immunosuppresseurs pour le traitement ou la prevention de rejets de greffes
NZ526216A (en) *	2000-11-03	2005-02-25	Univ Manchester	Selective glucocorticoid receptor agonists
US20020127263A1 (en) *	2001-02-27	2002-09-12	Wenda Carlyle	Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
EP2116228A1 (fr) *	2001-10-19	2009-11-11	Isotechnika Inc.	Nouveaux préconcentrés de microémulsion analogue de cyclosporine
EP1446113A4 (fr) *	2001-10-25	2006-12-06	Atherogenics Inc	Composes et methodes de traitement d'un rejet de greffe
US7682387B2 (en)	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en)	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en) *	2002-06-28	2006-09-19	Hobai Ion A	Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
PT1589031E (pt)	2002-07-16	2007-11-28	Biotica Tech Ltd	Produção de policétidos e outros produtos naturais
BR0314013A (pt) *	2002-09-06	2005-07-12	Abbott Lab	Equipamento médico contendo inibidor de hidratação
US8163726B2 (en) *	2002-09-18	2012-04-24	University Of Pennsylvania	Method of inhibiting choroidal neovascularization
US8202530B2 (en) *	2002-09-27	2012-06-19	Advanced Cardiovascular Systems, Inc.	Biocompatible coatings for stents
AR043504A1 (es) *	2003-03-17	2005-08-03	Novartis Ag	Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
JP4996249B2 (ja) *	2003-08-29	2012-08-08	ベロクシスファーマシューティカルズエー／エス	タクロリムスを含む改質放出組成物
KR20060085246A (ko)	2003-09-18	2006-07-26	마커사이트, 인코포레이티드	경공막 전달
EP1768662A2 (fr)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
WO2006086744A1 (fr)	2005-02-09	2006-08-17	Macusight, Inc.	Formulations pour un traitement oculaire
JP2008530145A (ja) *	2005-02-15	2008-08-07	ワイス	経口投与可能なｃｃｉ−７７９製剤
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
KR101914254B1 (ko) *	2005-02-18	2018-11-02	아브락시스 바이오사이언스, 엘엘씨	치료제의 조합 및 투여 방식, 및 조합 요법
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
CA2599547A1 (fr)	2005-03-11	2006-09-14	Biotica Technology Limited	Utilisation d'un compose
EP1871366A2 (fr) *	2005-03-21	2008-01-02	Macusight, Inc.	Systemes d'administration de medicaments destines au traitement de maladies ou de troubles
BRPI0609071A2 (pt) *	2005-04-12	2010-11-16	Elan Pharma Int Ltd	composicão estável de ciclosporina nanoparticulada, método para preparar uma ciclosporina nanoparticulada, uso da composição de ciclosporina nanoparticulada estável, e, composição de liberação controlada
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
EP1888137A2 (fr) *	2005-04-29	2008-02-20	Atrium Medical Corporation	Enrobage de diffusion de medicament utilisable avec un dispositif medical, et methodes de traitement d'une lesion vasculaire
US20080021078A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Methods and medicaments for administration of ibuprofen
WO2007012022A2 (fr) *	2005-07-18	2007-01-25	Horizon Therapeutics, Inc.	Forme posologique unitaire renfermant un melange d'ibuprofene et de famotidine
US8067451B2 (en)	2006-07-18	2011-11-29	Horizon Pharma Usa, Inc.	Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Unit dose form for administration of ibuprofen
JP5528708B2 (ja)	2006-02-09	2014-06-25	参天製薬株式会社	安定な製剤ならびにそれらを調製および使用する方法
JP5506378B2 (ja)	2006-03-23	2014-05-28	参天製薬株式会社	血管透過性に関連する疾患または病気のための製剤および方法
US8067033B2 (en)	2007-11-30	2011-11-29	Horizon Pharma Usa, Inc.	Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) *	2006-08-31	2010-11-25	Horizon Therapeutics, Inc.	NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
LT2552415T (lt)	2010-03-29	2016-12-27	Abraxis Bioscience, Llc	Vėžio gydymo būdai
CN102985086A (zh)	2010-03-29	2013-03-20	阿布拉科斯生物科学有限公司	增强药物递送和治疗剂有效性的方法
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
WO2011153010A1 (fr)	2010-06-04	2011-12-08	Abraxis Biosciences, Llc	Procédés de traitement du cancer du pancréas
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
US20130317053A1 (en) *	2011-01-31	2013-11-28	Osaka University	Externally-used drug for treating skin disorder and method for producing same
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US9220759B2 (en)	2012-02-23	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en)	2012-03-30	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (fr)	2012-09-07	2014-03-12	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.	Composés pour le traitement de troubles neurodégénératifs
ES2797376T3 (es)	2013-01-24	2020-12-02	Palvella Therapeutics Inc	Composiciones para la administración transdérmica de inhibidores de mTOR
MX384445B (es)	2013-09-24	2025-03-14	Giner Inc	Sistema para tratamiento con gas de un implante de células.
WO2016033549A2 (fr)	2014-08-28	2016-03-03	Lipocine Inc.	Compositions de (17-ss)-3-oxoandrost-4-èn-17-yl tridécanoate et leurs procédés de préparation et d'utilisation
WO2016033556A1 (fr)	2014-08-28	2016-03-03	Lipocine Inc.	Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016205423A2 (fr)	2015-06-15	2016-12-22	Lipocine Inc.	Composition et méthode pour l'administration orale de promédicaments androgènes
WO2017079736A1 (fr) *	2015-11-06	2017-05-11	The Trustees Of Columbia University In The City Of New York	Profilage de protéines exosomales pour la détection du rejet de greffe cardiaque
CA3043468C (fr)	2016-11-15	2021-06-22	Giner Life Sciences, Inc.	Dispositif de diffusion de gaz percutane adapte pour utilisation avec un implant sous-cutane
EP3544614A4 (fr)	2016-11-28	2020-08-05	Lipocine Inc.	Traitement oral à base d'undécanoate de testostérone
WO2018129364A1 (fr)	2017-01-06	2018-07-12	Palvella Therapeutics Llc	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
CN110603038A (zh)	2017-02-10	2019-12-20	塔姆山治疗公司	雷帕霉素类似物
US11642501B2 (en)	2017-05-04	2023-05-09	Giner, Inc.	Robust, implantable gas delivery device and methods, systems and devices including same
WO2020010073A1 (fr)	2018-07-02	2020-01-09	Palvella Therapeutics, Inc.	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
DK0562853T3 (da)	1992-03-27	1996-07-01	American Home Prod	29-Demethoxyrapamycin til fremkaldelse af immunsuppression
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB2278780B (en)	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
GB9601120D0 (en) *	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
DK0956034T3 (da) *	1996-07-30	2002-12-16	Novartis Ag	Farmaceutiske præparater til behandling af transplantatafstødning, autoimmune eller inflammatoriske tilstande omfattende cyclosporin A og 40-O-(2-hydroxyethyl)-rapamycin
EP1181034B1 (fr) *	1999-05-10	2010-07-21	Paolo Brenner	Combinaisons d'agents immunosuppresseurs pour le traitement ou la prevention de rejets de greffes

1997
- 1997-07-29 DK DK97937526T patent/DK0956034T3/da active
- 1997-07-29 PT PT01131018T patent/PT1208847E/pt unknown
- 1997-07-29 AT AT97937526T patent/ATE222502T1/de active
- 1997-07-29 DK DK01131018T patent/DK1208847T3/da active
- 1997-07-29 SI SI9730756T patent/SI1208847T1/sl unknown
- 1997-07-29 AT AT01131018T patent/ATE340586T1/de active
- 1997-07-29 PT PT97937526T patent/PT956034E/pt unknown
- 1997-07-29 EP EP97937526A patent/EP0956034B1/fr not_active Expired - Lifetime
- 1997-07-29 EP EP01131018A patent/EP1208847B8/fr not_active Expired - Lifetime
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 ES ES01131018T patent/ES2270948T3/es not_active Expired - Lifetime
- 1997-07-29 CA CA2261666A patent/CA2261666C/fr not_active Expired - Lifetime
- 1997-07-29 JP JP50851398A patent/JP3942641B2/ja not_active Expired - Lifetime
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/fr not_active Ceased
- 1997-07-29 DE DE69714861T patent/DE69714861T2/de not_active Expired - Lifetime
- 1997-07-29 NZ NZ333657A patent/NZ333657A/xx not_active IP Right Cessation
- 1997-07-29 ES ES97937526T patent/ES2182112T3/es not_active Expired - Lifetime
- 1997-07-29 DE DE69736750T patent/DE69736750T2/de not_active Expired - Lifetime
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/xx unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6455518B2 (en)	2002-09-24
DE69714861T2 (de)	2003-05-22
AU730781B2 (en)	2001-03-15
NZ333657A (en)	2000-05-26
EP0956034B1 (fr)	2002-08-21
EP1208847B8 (fr)	2007-02-14
DE69736750D1 (de)	2006-11-09
AU4012497A (en)	1998-02-20
PT1208847E (pt)	2007-07-24
DK0956034T3 (da)	2002-12-16
JP3942641B2 (ja)	2007-07-11
CA2261666A1 (fr)	1998-02-05
US6239124B1 (en)	2001-05-29
JP2000505806A (ja)	2000-05-16
ES2182112T3 (es)	2003-03-01
JP4149905B2 (ja)	2008-09-17
DK1208847T3 (da)	2007-01-08
ATE222502T1 (de)	2002-09-15
EP1208847A3 (fr)	2002-06-12
US20010008888A1 (en)	2001-07-19
EP1208847B1 (fr)	2006-09-27
ATE340586T1 (de)	2006-10-15
SI1208847T1 (sl)	2007-06-30
DE69736750T2 (de)	2007-08-16
EP0956034A1 (fr)	1999-11-17
DE69714861D1 (de)	2002-09-26
ES2270948T3 (es)	2007-04-16
HK1023720A1 (en)	2000-09-22
PT956034E (pt)	2002-12-31
JP2004210767A (ja)	2004-07-29
WO1998004279A1 (fr)	1998-02-05
EP1208847A2 (fr)	2002-05-29
CA2261666C (fr)	2010-09-14

Publication	Publication Date	Title
CY2391B1 (en)	2004-09-10	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin.
AU638253B2 (en)	1993-06-24	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP1149581A3 (fr)	2003-12-03	Utilisation de la rapamicine dans les vasculopathies et les xenotransplantations
NZ310767A (en)	2000-11-24	Use of an immunosuppressive or non-immunosuppressive pipecolic acid derivative for treating neurological disorders
WO1998002441A3 (fr)	1998-03-05	Elements et procedes pour traiter ou prevenir les mycoses pathogènes
PL292248A1 (en)	1992-07-27	Method of obtaining novel cyclosporines
ZA945673B (en)	1995-02-07	Pharmaceutical composition
IL122905A (en)	2003-07-06	Pharmaceutical compositions in the form of a solid dispersion comprising a rapamycin
HUP0000587A3 (en)	2001-12-28	Pharmaceutical composition containing tacrolimus (fk506)
ZA977671B (en)	1998-02-23	Cross-linked copolymers based on polycarboxylic polymers.
ATE233095T1 (de)	2003-03-15	Kombinationspraeparat, welches cyclosporin a oder fk-506 oder rapamycin und ein xanthinderivat enthaelt
DE69719320D1 (de)	2003-04-03	Kombination eines somatostatin analogs und eines rapamycins
AU4565000A (en)	2000-11-21	Organic compounds
SI0956034T1 (en)	2002-12-31	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin
EP0925071A4 (fr)	2000-09-13	Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires
IL81508A (en)	1991-03-10	Phytopathogenic antibiotic compositions comprising rifamycin derivatives